Y-Intercept (HK)’s Immuneering IMRX Stock Holding History

Y-Intercept (HK)’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,280	Closed	-$75.3K	–	1932
2026 Q1	$75.3K	Buy	+14,280	New	+$73.2K	﹤0.01%	1467
2024 Q3	–	Sell	-59,960	Closed	-$76.7K	–	1540
2024 Q2	$76.7K	Buy	+59,960	New	+$98.6K	﹤0.01%	1279
2023 Q2	–	Sell	-11,114	Closed	-$108K	–	1482
2023 Q1	$108K	Buy	+11,114	New	+$63.1K	0.01%	1048

Other funds holding IMRX

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

FCC

Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return

Berman McAleer Timonium, Maryland $864M AUM 22.02% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

FFN

Focus Financial Network Minneapolis, Minnesota $3.23B AUM 29.61% 1-Year Est. Return

Y-Intercept (HK)'s IMRX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 14,280 shares — an estimated $75.3K sold.

Y-Intercept (HK) first reported a position in IMRX in Q1 2023 and held it in 3 quarters. The position peaked at $108K in Q1 2023. 5 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Y-Intercept (HK) reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 14,280 Immuneering shares in Q2 2026, an estimated $75.3K.
Y-Intercept (HK) first reported a position in Immuneering in Q1 2023 and held it in 3 quarters.
Y-Intercept (HK)'s Immuneering position peaked at $108K in Q1 2023.
5 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.